Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LEDERLE ORAL CEPHALOSPORIN SUPRAX (CEFIXIME) APPROVED

Executive Summary

LEDERLE ORAL CEPHALOSPORIN SUPRAX (CEFIXIME) APPROVED on April 28 after a nearly three-year review at FDA. The initial NDA submission for Suprax was filed in June 1986. Lederle plans to launch the new third generation cephalosporin by the third quarter of 1989. Cefixime is licensed for marketing in the U.S. from the Japanese firm Fujisawa. Biocraft will manufacture the product for Lederle. Suprax is indicated for use in treating otitis media, acute bronchitis,acute exacerbation of chronic bronchitis, tonsilitis, urinary tract infections and pharyngitis. FDA approved the drug in 200 mg and 400 mg tablets for adults. The recommended dosage is one or two tablets a day. The recommended pediatric dose of the liquid suspension formulation is 8 mg/kg. Suprax is the second cephalosporin antibiotic approved by the FDA so far this year. Wyeth-Ayerst's cefpiramide was approved in late January; however, the company has indicated that its marketing plans for the drug are "indefinite." To date, FDA has approved three new chemical entities in 1989 -- the other approval was for Schering-Plough's Eulexin.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel